SAFETY AND IMMUNOGENICITY OF DIFFERENT IMMUNIZATION REGIMENS OF CVD 103-HGR LIVE ORAL CHOLERA VACCINE IN SOLDIERS AND CIVILIANS IN THAILAND

被引:82
作者
SUAREHAWARATANA, P
SINGHARAJ, P
TAYLOR, DN
HOGE, C
TROFA, A
KUVANONT, K
MIGASENA, S
PITISUTTITHAM, P
LIM, YL
LOSONSKY, G
KAPER, JB
WASSERMAN, SS
CRYZ, S
ECHEVERRIA, P
LEVINE, MM
机构
[1] UNIV MARYLAND,SCH MED,CTR VACCINE DEV,10 S PINE ST,BALTIMORE,MD 21201
[2] MAHIDOL UNIV,FAC TROP MED,CTR VACCINE TRIAL,BANGKOK 10700,THAILAND
[3] WALTER REED ARMY MED CTR,DEPT ENTER INFECT,WASHINGTON,DC 20307
[4] SWISS SERUM & VACCINE INST,BERN,SWITZERLAND
关键词
D O I
10.1093/infdis/165.6.1042
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Attenuated Vibrio cholerae oral vaccine CVD 103-HgR was well tolerated by 324 Thai soldiers and civilians. Most received a single 5 x 10(8) cfu dose, while 40 each received one or two 5 x 10(9) cfu doses. Vibriocidal antibody (the best correlate of immunity) seroconversion was lower in soldiers than civilians (P < .001). Increasing the vaccine dose to 5 x 1O(9) cfu raised the geometric mean titer (P < .00 1). A second 5 x 1O(9) cfu dose one week later did not notably increase seroconversions. Likelihood of seroconversion was inversely correlated with baseline vibriocidal titer (P < .001). CVD 103-HgR caused seroconversion in most subjects with baseline titers less-than-or-equal-to 1:40, including 100% of civilians after one 5 x 10(8) cfu dose, 79% of soldiers after one 5 x 10(9) cfu dose, and 45% of soldiers after one 5 x 10(8) cfu dose. In persons with elevated baseline titers, vibriocidal antibody seroconversion is not a sensitive measure of whether vaccine has boosted intestinal immunity; for such subjects, other measurements must be used. Study regimens in endemic areas should use a single 5 x 10(9) cfu dose.
引用
收藏
页码:1042 / 1048
页数:7
相关论文
共 25 条
  • [1] BENENSON AS, 1968, B WORLD HEALTH ORGAN, V38, P277
  • [2] BHAT P, 1972, GASTROENTEROLOGY, V62, P11
  • [3] B-SUBUNIT-WHOLE CELL AND WHOLE CELL-ONLY ORAL VACCINES AGAINST CHOLERA - STUDIES ON REACTOGENICITY AND IMMUNOGENICITY
    CLEMENS, JD
    STANTON, BF
    CHAKRABORTY, J
    SACK, DA
    KHAN, MR
    HUDA, S
    AHMED, F
    HARRIS, JR
    YUNUS, M
    KHAN, MU
    SVENNERHOLM, AM
    JERTBORN, M
    HOLMGREN, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1987, 155 (01) : 79 - 85
  • [4] FIELD TRIAL OF ORAL CHOLERA VACCINES IN BANGLADESH - RESULTS FROM 3-YEAR FOLLOW-UP
    CLEMENS, JD
    SACK, DA
    HARRIS, JR
    VANLOON, F
    CHAKRABORTY, J
    AHMED, F
    RAO, MR
    KHAN, MR
    YUNUS, M
    HUDA, N
    STANTON, BF
    KAY, BA
    WALTER, S
    EECKELS, R
    SVENNERHOLM, AM
    HOLMGREN, J
    [J]. LANCET, 1990, 335 (8684) : 270 - 273
  • [5] RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF THE LIVE ORAL CHOLERA VACCINE STRAIN CVD-103-HGR IN SWISS ADULTS
    CRYZ, SJ
    LEVINE, MM
    KAPER, JB
    FURER, E
    ALTHAUS, B
    [J]. VACCINE, 1990, 8 (06) : 577 - 580
  • [6] CHOLERA IN AFRICA - LESSONS ON TRANSMISSION AND CONTROL FOR LATIN-AMERICA
    GLASS, RI
    CLAESON, M
    BLAKE, PA
    WALDMAN, RJ
    PIERCE, NF
    [J]. LANCET, 1991, 338 (8770) : 791 - 795
  • [7] GRACEY M, 1973, AM J CLIN NUTR, V26, P1170
  • [8] A RECOMBINANT LIVE ORAL CHOLERA VACCINE
    KAPER, JB
    LOCKMAN, H
    BALDINI, MM
    LEVINE, MM
    [J]. BIO-TECHNOLOGY, 1984, 2 (04): : 345 - 349
  • [9] RECOMBINANT ATTENUATED VIBRIO-CHOLERAE STRAINS USED AS LIVE ORAL VACCINES
    KAPER, JB
    LEVINE, MM
    [J]. RESEARCH IN MICROBIOLOGY, 1990, 141 (7-8) : 901 - 906
  • [10] LEVINE M M, 1988, Lancet, V2, P467